Unbiased Discovery and Validation of Serum Auto Antibodies in Patients with Rheumatic Immune Related Adverse Events Due to Immune Checkpoint Inhibitors

Sponsor:

MUSC

Sponsor Study ID:

103414

CTO #:

103414

NCT Number:

Phase:

N/A

Protocol Type:

Basic Science

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

Create an MUSC biorepository of specimens for patients receiving checkpoint inhibitors (CPI) with prioritization of specimen collection during irAE s. An IRB compliant protocol to enroll patients will allow us to acquire initial blood samples (PBMC and serum) from consenting MUSC oncology patients receiving CPI as part of their standard of care for their cancer. Additional collection time points will be obtained from patients at presentation and longitudinally after development of irAE s. Prioritization will be given to patients with rheumatic irAE s (i.e. arthritis, skin rash, inflammatory eye disease), and synovial fluid samples will be collected from patients who develop inflammatory arthritis on irAE therapy if they consent.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)